Skip to content

Study on the efficacy and safety of continuous circulation peritoneal dialysis and tidal peritoneal dialysis in the treatment of chronic renal failure

Study on the efficacy and safety of continuous circulation peritoneal dialysis and tidal peritoneal dialysis in the treatment of renal failure

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000031010
Enrollment
Unknown
Registered
2020-03-21
Start date
2020-03-21
Completion date
Unknown
Last updated
2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic renal failure

Interventions

CCPD group:continuous circulation peritoneal dialysis
TPD group:tidal peritoneal dialysis

Sponsors

Tianjin Fifth Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. It conforms to the diagnostic standard of chronic renal failure formulated by nephrology branch of Chinese society of traditional Chinese medicine in 2006; 2. Have uremic symptoms, including anorexia, nausea or vomiting, fatigue, etc; 3. The glomerular filtration rate was 0-15 ml / min; 4. No acute water poisoning, severe acidosis, hyperkalemia, etc;

Exclusion criteria

Exclusion criteria: 1. Difficult to control diabetes, hypertension, active infection and any other patients with clinically significant abnormalities; 2. Patients with peritoneal dialysis contraindications; 3. Patients with active advanced malignant tumor; 4. Peritonitis, recent abdominal surgery; 5. Hemodialysis to peritoneal dialysis; 6. Pregnant women; 7. Before selection, the drugs and blood products that affect the function of platelets and coagulation factors or the drugs that affect the parameters of Hematology should be used; 8. Taking other experimental drugs or participating in other clinical trials within one month before the inclusion of the study; 9. The person in charge of clinical research thinks it is not suitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
urea;creatinine;ß 2-microglobulin;hemoglobin;potassium;albumin;Ultrafiltration volumne;

Countries

China

Contacts

Public ContactYang Wen

Tianjin Fifth Central Hospital

326388259@qq.com+86 13752283326

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026